Answers are grounded in this paper and cite their sources.
Cefazolin is a first-generation cephalosporin antibiotic commonly used for the treatment of various bacterial infections. It is generally well-tolerated, with minimal side effects. However, hemolytic anemia is an extremely rare but potentially lifethreatening complication of cefazolin therapy. We report a case of a 83-year-old male patient who developed severe hemolytic anemia during cefazolin therapy for urinary tract infection. The diagnosis was confirmed by laboratory findings and the resolution of hemolysis after discontinuation of cefazolin. The direct antiglobulin test was negative, suggesting a non-immune mechanism of hemolysis. The pathophysiology of cefazolin induced hemolytic anemia is not fully understood, but it may involve hapten formation, cross-reactivity with penicillins, or drug metabolites. Clinicians should be aware of this rare adverse reaction and consider it in patients who develop unexplained anemia during or after cefazolin therapy
No takes yet. Share an insight, caveat, or question.
Sean McCormack (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: